Inhibition of protein tyrosine kinases or protein kinase C prevents nonspecific killer T lymphocyte-mediated tumoricidal activity.
The signal transduction events which govern major histocompatibility complex-unrestricted tumour cell destruction by nonspecific killer T lymphocytes induced with anti-CD3 antibody have not yet been determined. In this study we used pharmacologic inhibitors to investigate the role of protein tyrosine kinases (PTK) and protein kinase C (PKC) in this process. The PTK-inhibitors herbimycin A, genistein, and methyl 2,5-dihydroxycinnamate blocked anti-CD3-activated killer T (AK-T) lymphocyte-mediated killing of tumour target cells. The PKC-inhibitors staurosporine, calphostin C, and myristoylated PKC pseudosubstrate peptide, as well as PKC desensitization by phorbol 12-myristate 13-acetate pretreatment, also suppressed the cytolytic effector function of AK-T lymphocytes. Lack of tumoricidal activity was not due to reduced AK-T lymphocyte binding to tumour target cells but was associated with the abrogation of granule exocytosis, indicating that PTK and PKC are involved in the postbinding process which results in delivery of the 'lethal hit' by AK-T lymphocytes.
Stewart
B H
BH
Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Hoskin
D W
DW
D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D016227:Benzoquinones; D002934:Cinnamates / Q000494:pharmacology; D005260:Female; D019833:Genistein; D053804:Granzymes; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007529:Isoflavones / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology; D047029:Lactams, Macrocyclic; D051379:Mice; D008810:Mice, Inbred C57BL; D016853:Muromonab-CD3 / Q000494:pharmacology*; D009369:Neoplasms / Q000276:immunology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives; D012697:Serine Endopeptidases / Q000378:metabolism; D015398:Signal Transduction
D016227:Benzoquinones; D002934:Cinnamates; D007166:Immunosuppressive Agents; D007529:Isoflavones; D047029:Lactams, Macrocyclic; D016853:Muromonab-CD3; D011809:Quinones; D017828:Rifabutin; C067472:methyl 2,5-dihydroxycinnamate; C020754:herbimycin; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C; D053804:Granzymes; D012697:Serine Endopeptidases